NANOSTRUCTURED LIPID CARRIERS: THE FRONTIERS IN DRUG DELIVERY

  • KARNATI V CHANDANA Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.
  • N. VISHAL GUPTA Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.
  • SANDEEP KANNA Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.

Abstract

By the modification of solid-lipid nanoparticles (SLNs), the nano-structured lipid carriers (NLCs) were obtained by the modification of nanostructured that hold the qualities of the SLN, increases the stability of the drug, and prevents drug leakage. The limitations of the drugs that are delivered in the body using different routes are poor solvency, first pass metabolism, and poor bioavailability hence to overcome these limitations NLCs were prepared. Oral, topical, transdermal, ocular, and parenteral are the different routes through which nanobased systems are delivered. Spatially incompatible liquid lipids and solid lipids are blended and NLCs were prepared. It stays solid at room temperature. The advantages of for drug therapy over conventional carriers NLCs are increased solubility, improved bioavailability. This review describes about the NLC, its advantages and disadvantages, types, NLC techniques, mode of action, and applications of NLC. Imperfect, amorphous, and multiple types are the main three types of NLCs. Lipids, liquid lipids, solid lipids, Emulsifiers, ultraviolet (UV) blockers, and aqueous medium were the excipients used. Microemulsion technique, microemulsion based SLN/NLC preparations, solvent diffusion method, high-pressure homogenization (HPH), hot and cold homogenization techniques, and melt emulsification method are the techniques used for the preparation of NLC. The applications of NLCs are for ocular, brain targeting, topical, cancer therapy, cosmetics, and analgesia.

Keywords: Nano structured lipid carriers,, Solid lipid nanoparticles,, Solid lipids,, Liquid lipids.

References

1. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur J Pharm Sci 2009;38:138-46.
2. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH. Lipid nanocarriers for dermal delivery of lutein: Preparation, characterization, stability and performance. Int J Pharm 2011;414:267-75.
3. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627-38.
4. Sezer AD. Recent Advances in Novel Drug Carrier Systems. Rijeka, Croatia: InTech; 2012.
5. Pradhan M, Singh D, Singh MR. Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches. J Control Release 2013;170:380-95.
6. Achieve HT. Characterizing release from lipid-based formulations. In: Hauss D, editor. Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water Soluble Drugs. Boca Raton: CRC Press; 2007. p. 241.
7. Augustin MA, Sanguansri L, Lockett T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Ann N Y Acad Sci 2013;1290:107-12.
8. Babazadeh A, Ghanbarzadeh B, Hamishehkar H. Novel nanostructured lipid carriers as a promising food grade delivery system for rutin. J Funct Foods 2016;26:167-75.
9. Belfrage P, Vaughan M. Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides. J Lipid Res 1969;10:341-4.
10. Bouwmeester H, Dekkers S, Noordam MY, Hagens WI, Bulder AS, de Heer C, et al. Review of health safety aspects of nanotechnologies in food production. Regul Toxicol Pharmacol 2009;53:52-62.
11. Ali H, El-Sayed K, Sylvester PW, Nazzal S. Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: Evidence studies by differential scanning calorimetry (DSC) and proton nuclear magnetic resonance spectroscopy ((1)H NMR). Colloids Surf B Biointerfaces 2010;77:286-97.
12. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006;110:296-306.
13. Cui Z, Mumper RJ. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm Res 2002;19:939-46.
14. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010;6:9-24.
15. Müller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161-70.
16. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int J Pharm 2008;357:295-304.
17. Patidar A, Thakur DS, Kumar P, Verma J. A review on novel lipid based carrier. Int J Pharm Pharm Sci 2010;2:30-5.
18. R.H. Müller and J.S. Lucks, European Patent 0605497 (1996).
19. Müller RH, Runge SA, Ravelli V. German Patent Application DE 19819273 A1; 1998.
20. Penkler L, Müller RH, Runge SA, Ravelli V. Extended Patent on the Basis of (2), PCT Application PCT/EP99/02892; 1999.
21. M.R. Gasco, Patent 5250236 (1993).
22. Boltri L, Canal T, Esposito PA, Carli F. Lipid nanoparticles: Evaluation of some critical formulation parameters. Proc Int Symp Control Rel Bioact Mater 1993;20:346-7.
23. Carmona-Ribeiro AM. Biomimetic nanoparticles: Preparation, characterization and biomedical applications. Int J Nanomedicine 2010;5:249-59.
24. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul 2008;2:120-35.
25. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
26. Jores K, Mehnert W, Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: A nuclear magnetic resonance and electron spin resonance study. Pharm Res 2003;20:1274-83.
27. Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ. Solid lipid nanoparticles and nanostructured lipid carriers – innovative generations of solid lipid carriers. Curr Drug Deliv 2008;5:324-31.
28. Lancelot A, Sierra T, Serrano JL. Nanostructured liquid-crystalline particles for drug delivery. Expert Opin Drug Deliv 2014;11:547-64.
29. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84.
30. Liu C H, Wu CT. Optimization of nanostructured lipid carriers for lutein delivery. Colloid Surf A 2010;353:149-56.
31. Mk Sahu, Gc Soni, et al International Journal For Pharmaceutical Research Scholars (Ijprs), 2012, 1(3).
32. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002;238:241-5.
33. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S, et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007;59:444-53.
34. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215-28.
35. Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M. Glucocorticoid entrapment into lipid carriers – characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release 2004;97:493-502.
36. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009;26:523-80.
37. Gregoriadis G, Florence AT, Patel HM. Liposomes in drug delivery. In: Florence AT, Chur GG, editors. Drug Targeting and Delivery. Chur: Harwood Academic Publishers GmbH; 1993.
38. Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005;18:209-19.
39. Subramanian S, Anandam S, Krishnamoorthy K, Rajappan M. Nanosponges: A novel class of drug delivery system – review. J Pharm Pharm Sci 2012;15:103-11.
40. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release 2005;108:112-20.
41. Chaudhry Q, Castle L. Food applications of nanotechnologies: An overview of opportunities and challenges for developing countries. Trends Food Sci Technol 2011;22:595-603.
42. Chaudhry Q, Scotter M, Blackburn J, Ross B, Boxall A, Castle L, et al. Applications and implications of nanotechnologies for the food sector.Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2008;25:241-58.
43. Chaudhry Q, Castle L, Watkins R. Nanotechnologies in Food. London: Royal Society of Chemistry; 2010.
44. Chawla V, Saraf SA. Glyceryl behenate and its suitability for production of aceclofenac solid lipid nanoparticles. J Am Oil Chem Soc 2011;88:119-26.
45. Garcia-Fuentes M, Alonso MJ, Torres D. Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures. J Colloid Interface Sci 2005;285:590-8.
46. González-Mira E, Nikoli? S, García ML, Egea MA, Souto EB, Calpena AC, et al. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci 2011;100:242-51.
47. Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Aspects 2008;315:210-6.
48. Higuchi WI. Analysis of data on the medication release from ointments. J Pharm Sci 1962;51:802-4.
49. Jackson CL, McKenna GB. The melting behavior of organic materials confined in porous solids. J Chem Phys 1990;93:9002-11.
50. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci 2009;71:349-58.
51. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: Effect of particle size, cell line and cell density. J Control Release 2001;71:39-51.
52. Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997;14:458-62.
53. Radtke M, Muller RH. Nanostructured lipid carriers: The new generation of lipid drug carriers. New Drugs 2001;2:48-52.
54. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – Structural investigations on two different carrier systems. Biomed Mater Eng 2005;15:393-402.
55. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54 Suppl 1:S131-55.
56. Jenning V, Schäfer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties. J Control Release 2000;66:115-26.
57. Tsai MJ, Wu PC, Huang YB, Chang JS, Lin CL, Tsai YH, et al. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 2012;423:461-70.
58. Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci 2008;30:157-65.
59. Pokharkar VB, Jolly MR, Kumbhar DD. Engineering of a hybrid polymer-lipid nanocarrier for the nasal delivery of tenofovir disoproxil fumarate: Physicochemical, molecular, microstructural, and stability evaluation. Eur J Pharm Sci 2015;71:99-111.
60. Mishra BJ, Kaul A, Trivedi P. L-cysteine conjugated poly L-lactide nanoparticles containing 5-fluorouracil: Formulation, characterization, release and uptake by tissues in vivo. Drug Deliv 2015;22:214-22.
61. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: Safety on drug delivery. Nanomedicine 2009;5:394-401.
62. Müller RH, Souto EB, Radtke M. PCT Application PCT/EP00/04111; 2000.
63. Rosenblatt KM, Bunjes H. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the ?-modification. Mol Pharm 2009;6:105-20.
64. Kakar S, Batra D, Singh R. Preparation and evaluation of magnetic microspheres of mesalamine for colon drug delivery. J Acute Dis 2013;2:226-31.
65. Obeidat WM, Schwabe K, Müller RH, Keck CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2010;76:56-67.
66. Oldrich C, Bakowski U, Lehr CM, Müller RH, Kneuer C. Cationic solid- lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 2001;77:345-55.
67. Acener M. Preparation, characterization and physicochemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie 2006;61:375.
68. Shekhawat PB. Preparation and evaluation of clotrimazole nanostructured lipid carrier for topical delivery. Int J Pharm Bio Sci 2013;4:407-16.
Statistics
318 Views | 136 Downloads
Citatons
How to Cite
KARNATI V CHANDANA, N. VISHAL GUPTA, and SANDEEP KANNA. “NANOSTRUCTURED LIPID CARRIERS: THE FRONTIERS IN DRUG DELIVERY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 7, May 2019, pp. 8-12, doi:10.22159/ajpcr.2019.v12i7.33595.
Section
Review Article(s)